Empirical Asset Management LLC Purchases New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Empirical Asset Management LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, HoldingsChannel reports. The fund acquired 22,810 shares of the biopharmaceutical company’s stock, valued at approximately $1,091,000.

Several other institutional investors have also added to or reduced their stakes in the company. Congress Asset Management Co. raised its holdings in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after buying an additional 1,988,238 shares during the period. Handelsbanken Fonder AB boosted its holdings in Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after acquiring an additional 856,200 shares during the period. Boston Trust Walden Corp grew its position in Halozyme Therapeutics by 54.0% in the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock valued at $39,073,000 after acquiring an additional 239,321 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares during the period. Finally, South Street Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the third quarter worth $9,812,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

HALO stock opened at $54.80 on Friday. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The firm has a market cap of $6.97 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.40 and a beta of 1.24. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The firm has a 50-day simple moving average of $49.62 and a two-hundred day simple moving average of $54.11.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $60.89.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.70% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.